SEC charges Bristol-Myers Squibb over FCPA violations

Bristol-Myers Squibb will pay the US Securities and Exchange Commission (SEC) US$14 million to settle charges that "its joint venture in China made cash payments and provided other benefits to health care providers at state-owned and state-controlled hospitals in exchange for prescription sales".


Get unlimited access to all Global Investigations Review content